Diagnostic techniques based on PCR have two major problems: false-positive reactions due to contamination with DNA fragments from previous PCRs (amplicons) and false-negative reactions caused by inhibitors that interfere with the PCR. We have improved our previously reported PCR based on the amplification of a fragment of the Mycobacterium tuberculosis complex-specific insertion element IS6110 with respect to both problems. False-positive reactions caused by amplicon contamination were prevented by the use of uracil-Nglycosylase and dUTP instead of dTTP. We selected a new set of primers outside the region spanned by the formerly used primers to avoid false-positive reactions caused by dTTP-containing amplicons still present in the laboratory. With this new primer set, 16 copies of the IS6110 insertion element, the equivalent of two bacteria, could be amplified 1010 times in 40 cycles, resulting in a mean efficiency of 77% per cycle. To detect the presence of inhibitors of the Taq polymerase, which may cause false-negative reactions, part of each sample was spiked with M. tuberculosis DNA. The DNA purification method using guanidinium thiocyanate and diatoms effectively removed most or all inhibitors of the PCR. However, this was not suitable for blood samples, for which we developed a proteinase K treatment followed by phenol-chloroform extraction. This method permitted detection of 20 M. tuberculosis bacteria per ml of whole blood. Various laboratory procedures were introduced to reduce failure or inhibition of PCR and avoid DNA cross contamination. We have tested 218 different clinical specimens obtained from patients suspected of having tuberculosis. The samples included sputum (n = 145), tissue biopsy samples (n = 25), cerebrospinal fluid (n = 15), blood (n = 14), pleural fluid (n = 9), feces (n = 7), fluid from fistulae (n = 2), and pus from a wound (n = 1). The results obtained by PCR were consistent with those obtained with culture, which is the "gold standard." We demonstrate that PCR is a useful technique for the rapid diagnosis of tuberculosis at various sites.
Timely identification of infection with Mycobacterium tuberculosis is important because of the need to make decisions regarding management such as beginning antituberculosis drug therapy, isolation precautions, and prophylaxis. The outcome for the patient could be improved if fast, simple, and reliable tests could be developed. The diagnosis of extrapulmonary tuberculosis and tuberculoid meningitis is difficult, and the definitive diagnosis depends on culture of the mycobacteria, which is time-consuming and not always available.
We and others have recently reported on the use of PCR for the detection and identification of M. tuberculosis complex in clinical samples (2-5, 7, 8, 13, 19, 22, 23, 25) . This is a rapid and sensitive technique. The exquisite sensitivity of the PCR may also be a drawback: contamination of the laboratory with amplified DNA from previous PCRs (amplicons) may cause false-positive results. In this paper, we describe the use of uracil-N-glycosylase (UNG) (10) and dUTP instead of dTTP to prevent false-positive results due to amplicon contamination. We have extended our work on the quality control of the performance of PCR and have developed a DNA purification method for blood and feces samples. We have used this technically improved PCR in clinical samples from patients suspected of having tuberculosis by comparing the PCR results with the results of Ziehl-Neelsen (ZN) staining and culture.
MATERIALS AND METHODS
Bacterial strains. The same mycobacterial and nonmycobacterial strains as described previously (8) were used for the specificity testing.
Clinical samples. Sputum samples from 92 patients suspected of having tuberculosis were obtained from the Tuberculosis Division, Bangkok, Thailand. Samples were transported by air at -20°C. The other clinical samples were sent from various university hospitals in The Netherlands and included sputum (n = 53), tissue biopsy samples (n = 25), cerebrospinal fluid (n = 15), EDTA-blood (n = 14), pleural fluid (n = 9), feces (n = 7), fluid from fistulae (n = 2), and pus from a wound (n = 1). All samples were kept at -20°C.
Decontamination of sputum for culture. The sputum samples from Bangkok were decontaminated with oxalic acid. A swab was inserted into the sputum sample and then placed in 5% oxalic acid for 20 min at 25°C. The swab was then incubated in 5% Na citrate for 10 min at 25°C.
The sputum samples from The Netherlands were decontaminated, depending on the preference of the laboratory, by the NaOH Petroff method (6, 15) , by the sodium laurylsulfate method (6, 16) , or with NaOH-sodium citrate-N-acetyl-Lcysteine (9, 24) . In all these cases, samples were concentrated by centrifugation after decontamination. Pretreatment of clinical samples containing blood. Clinical samples which contained visible traces of blood were treated with a lysis buffer consisting of 1% Triton X-100 in 20 mM Tris-HCl (pH 8.3) as previously described (8) .
DNA purification from clinical samples. Clinical samples (other than sputum, tissue biopsy samples, blood, and feces) and decontaminated (9) sputum pellets (100 p.I) were mixed with 900 p.l of a lysis buffer containing approximately 5 M guanidinium thiocyanate, 1% Triton X-100, 50 mM Tris-HCl (pH 6.4), and 20 mM EDTA (L6 lysis buffer [1] ). DNA was purified according to the guanidinium thiocyanate method using 20 p.l of diatoms (1) . DNA was eluted from the diatoms in two steps with 60 and 40 pul of Tris-EDTA (TE) buffer (10 mM Tris-HCl [pH 8.3], 1 mM EDTA).
Treatment of biopsy samples. Biopsy samples (1 to 15 mg) were incubated for 1 h at 60°C in a mixture of 0.1 mg of proteinase K per ml, 0.5% Triton X-100, and 20 mM Tris-HCl (pH 8.3). The biopsy material was further disrupted by adding 900 p.l of L6 lysis buffer and 500 of zirconium beads (0.1-mm diameter) (Biospec Products, Bartlesville, Okla.). The mixture was shaken in a mechanical disruptor (MiniBeadBeater model 3110; Biospec Products) for 3 min. After the zirconium beads had settled, the DNA was purified from the supernatant by the guanidinium thiocyanate method (1) .
Treatment of blood and feces. Blood and feces were treated essentially as described by Meredith and coworkers (12) .
EDTA-blood (600 p.l) or feces (600 p.l) was mixed with 250 of TE buffer and incubated with 100 pul of a 10-timesconcentrated stock proteinase K digestion buffer (1 mg of proteinase K per ml, 5% Triton X-100, and 200 analyzed directly after the final cycle, the vials were incubated for a minimum of 1 h at 72°C.
The quality of the PCR mix was tested by amplification of a series of 1,000, 100, 10 and 1 fg of M. tuberculosis DNA per vial. Ten Detection of amplified DNA. The PCR products were analyzed by agarose gel electrophoresis on 2% agarose gels (8) . The results were recorded by Bio-print photodocumentation and when necessary stored in the image storage system (Vilber-Lourmat, Marne-la-Vallee, France).
For comparison of PCR results, the intensity of the PCR products was compared visually with the intensity of the PCR products of the positive controls. An intensity equal to or greater than that of the product of 100 fg of M. tuberculosis DNA was scored 2+, an intensity between those of the products of 100 and 10 fg of M. tuberculosis DNA was scored +, and an intensity less than that of 10 fg of M. tuberculosis DNA was scored +. For efficiency calculations, the amount of PCR product was more accurately determined by spot quantification, by interpolation with a standard curve using the Bio-profile software (Vilber-Lourmat). The standard curve was constructed employing the amounts of DNA from the fragments of the HaeIII-digested XX174 replicative form molecular size marker (New England Biolabs, Beverly, Md.).
The PCR results with clinical samples were confirmed by dot blot hybridization with a biotin-labeled oligonucleotide probe.
Oligonucleotide labeling with biotin. The oligonucleotide PtlO (5'-AGCACGAYTCGGAGTGGGCA-3'), which is situated within the 541-bp fragment and corresponds to bp 134 to 153 of the insertion sequence IS6110 of M. tuberculosis, was tail labeled at the 3' end of the DNA with biotin-16-dUTP by using the enzyme terminal transferase (18 To demonstrate the gravity of amplicon contamination we tested 10 plA of 1,000-fold serial dilutions of a 15-ng/pl 541-bp amplicon solution in PCR (Fig. 1A) . This amplicon solution was prepared by using 1,000 fg of M. tuberculosis DNA as a template in a PCR. We chose to start with a 1,000-fold dilution since 10 of a 100-fold dilution of the 541-bp amplicon solution could contain enough template DNA (2 fg) to give a positive reaction in PCR, due to the amplification of M.
tuberculosis DNA. Figure 1A shows The minimal amount of UNG necessary to break down contaminating amplicons was investigated by amplification of 10 ,u of the amplicon dilutions mentioned above in the presence of 0.5, 0.2, 0.1, 0.05, and 0.01 U of UNG. Panels B and C of Fig. 1 show that 0.01 U of UNG was able to break down 150 pg of 541-bp amplicons. The use of UNG did not affect the sensitivity of the PCR, as shown in Fig. 1A and B where the amplicon bands in lanes 8, 9, and 10 are of equal intensity. We performed PCR with 1,000, 100, 10, and 1 fg of M. tuberculosis DNA in the absence and presence of UNG. The same sensitivity was seen in both PCRs.
Stability of the PCR mix. For routine diagnosis it is necessary to prepare a batch of ready-for-use PCR vials and to test the quality of the batch before using it for clinical samples. We found it convenient to make batches of 200 vials. We consider the batch of sufficient quality if 10 fg of M. tuberculosis DNA can be amplified, resulting in a visible band in agarose gel electrophoresis, if 150 pg of 541-bp amplicon can be degraded, and if TE controls are negative.
We tested the stability of the PCR mix at different temperatures. We kept mixes at -20 or +4°C for 12 weeks, 18 or 37°C
for up to 1 week and performed a PCR with 1,000, 100, and 10 fg of M. tuberculosis DNA. The quality of PCR mixes that had been stored for 12 weeks at -20°C was the same as that of freshly prepared mixes. PCR mixes were stable at 4°C for 1 week, after which the quality of the mix decreased: 10 fg of M. tuberculosis DNA could not be detected. The stability of the PCR mixes stored at 20°C (room temperature) and 37°C
deteriorated within 24 h (results not shown). These experiments show that mixes can be stored for at least 3 months in the freezer and up to 1 week on ice. The effect of repeated thawing and freezing on the stability of the PCR mix was also tested. Thawing occurred at room temperature over 30 min, during which time the contents of the vial were at 20°C for about 10 min. After three cycles of thawing and freezing, the quality of the mix was unaffected, but it deteriorated after four or more cycles (results not shown). This means that an accidental thawing is not harmful for the PCR mix.
Sensitivity of PCR for clinical samples. To determine the detection limit of the PCR in clinical samples, we divided samples into four portions and spiked three portions with different amounts of M. tuberculosis bacteria (1,000, 100, and 10 per portion) before sample treatment. Our samples were four sputum samples (1 ml per portion), one liver biopsy sample (10 mg per portion), and one feces sample (600 ,ul per portion) from patients suffering from diseases other than tuberculosis and one blood sample (600 RI per portion) from a healthy individual. PCRs were performed with 10-pI portions (1/10 of the volume) of the treated sample. To detect the presence of inhibitors, 10 p1 of the treated nonspiked sample was tested in the presence of 10 fg of M. tuberculosis DNA. In all cases the spiked DNA could be detected, indicating that PCR was not inhibited. In the liver biopsy sample, feces, and two sputum samples the detection limit was 10 M. tuberculosis bacteria per reaction vial. In the other two sputum samples and the blood the detection limit was one bacterium per reaction vial (results not shown).
PCR results compared with those of culture and ZN staining. Culture provides the "gold standard" for the diagnosis of infections with M. tuberculosis. We have tested 218 clinical specimens from patients suspected of having tuberculosis. 
"Six sputum samples from Thailand, one biopsy sample, and one feces sample contained inhibiting components.
"One Mycobacteriunm fortuitum, one Mycobacterium chelonae, and three unidentified mycobacterial strains were cultured.
One Mycobacterilum avium and two unidentified mycobacterial strains were cultured. " Mycobacteriunm gordoniae was cultured.
"M. av'ium was cultured in all cases.
Specimens were obtained from a wide variety of sites, and the results are shown in Table 2 Quality control of the PCR mix and the performance of the amplification itself is mandatory if routine PCR is to replace culture for the diagnosis of tuberculosis.
